Inhibiting Histone and DNA Methylation Improves Cancer Vaccination in an Experimental Model of Melanoma.
Ontology highlight
ABSTRACT: Immunotherapy has improved the treatment of malignant skin cancer of the melanoma type, yet overall clinical response rates remain low. Combination therapies could be key to meet this cogent medical need. Because epigenetic hallmarks represent promising combination therapy targets, we studied the immunogenic potential of a dual inhibitor of histone methyltransferase G9a and DNA methyltransferases (DNMTs) in the preclinical B16-OVA melanoma model. Making use of tumor transcriptomic and functional analyses, methylation-targeted epigenetic reprogramming was shown to induce tumor cell cycle arrest and apoptosis in vitro coinciding with transient tumor growth delay and an IFN-I response in immune-competent mice. In consideration of a potential impact on immune cells, the drug was shown n
SUBMITTER: De Beck L
PROVIDER: S-EPMC9134079 | biostudies-literature | 2022
REPOSITORIES: biostudies-literature
ACCESS DATA